Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)

Innate Pharma has reported Other Non-Current Assets for 9 years, with the latest figure at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Assets rose 79.41% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (up 79.41% YoY), and the FY2025 full-year result was $1.1 million, up 79.41% from the prior year.
• Other Non-Current Assets for Q4 2025 stood at $1.1 million, up from $653140.7 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.1 million in Q4 2025, with the low at $91535.4 in Q2 2024.
• Historically, Other Non-Current Assets has averaged $338193.5 across 5 years, with a median of $164149.6 in 2021.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets plunged 99.82% — and 2025, when it jumped 613.54%.
• Innate Pharma's Other Non-Current Assets stood at $169307.7 in 2021, then slipped by 10.21% to $152016.9 in 2022, then plunged by 38.42% to $93606.8 in 2023, then surged by 556.41% to $614442.4 in 2024, then jumped by 79.41% to $1.1 million in 2025.
• The last three Other Non-Current Assets figures came in at $1.1 million (Q4 2025), $653140.7 (Q2 2025), and $614442.4 (Q4 2024), per Business Quant data.